SNBP - Sun BioPharma's SBP-101 Fast Track'd for type of pancreatic cancer June, 30 2020 04:58 PM Sun BioPharma Inc The FDA designates Sun BioPharma's (OTCQB:SNBP) lead candidate SBP-101 for Fast Track review for the treatment of patients with pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.More news on: Sun BioPharma, Inc., Healthcare stocks news, Read more ...